Pages • 1
Ligand Pharmaceuticals Ligand Pharmaceuticals Questions 1. Describe what you believe is implied by the term “ engagement risk.” What are the key factors likely considered by Deloitte and other audit firms when assessing engagement risk? How, if at all, are auditors’ professional responsibilities affected when a client poses a higher than normal degree of engagement.